ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
97,883.90
0.10%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Sonnet BioTherapeutics Holdings Inc (SONN) Cotización

Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc (SONN)

NASDAQ
2.98
0.09
(3.11%)
Cerrado 23 Noviembre 3:00PM
Delayed by 15 minutes
2.95
-0.03
(-1.01%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
2.98
Postura de Compra
2.91
Postura de Venta
3.19
Volume Operado de la Acción
44,327
2.88 Rango del Día 3.00
2.50 Rango de 52 semanas 18.7192
Capitalización de Mercado [m]
1.938M
Precio Anterior
2.89
Precio de Apertura
2.99
Hora
5
@
3
Última hora de negociación
Volumen financiero
US$ 130,438
Precio Promedio Ponderado
2.9426
Volumen promedio (3 m)
500,259
Acciones en circulación
650,313
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.10
Beneficio por acción (BPA)
-28.96
turnover
148k
Beneficio neto
-18.83M

Acerca de Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Management Consulting Svcs
Sitio web
www.sonnetbio.com
Sede
Wilmington, Delaware, USA
Fundado
2020
Sonnet BioTherapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SONN. The last closing price for Sonnet BioTherapeutics was US$2.89. Over the last year, Sonnet BioTherapeutics shares have traded in a share price range of US$ 2.50 to US$ 18.7192.

Sonnet BioTherapeutics currently has 650,313 shares in issue. The market capitalisation of Sonnet BioTherapeutics is US$1.88 million. Sonnet BioTherapeutics has a price to earnings ratio (PE ratio) of -0.10.

SONN Últimas noticias

Más noticias

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic...

12 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

08 Noviembre 2024
Edgar (US Regulatory)

Form 424B4 - Prospectus [Rule 424(b)(4)]

07 Noviembre 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

06 Noviembre 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...

06 Noviembre 2024
GlobeNewswire Inc.

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

06 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 Noviembre 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory...

06 Noviembre 2024
GlobeNewswire Inc.

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

04 Noviembre 2024
Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933

28 Octubre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.005-0.1675041876052.9853.52.51594692.89593705CS
4-3.43-53.51014040566.41102.513464043.7026756CS
12-2.788-48.33564493765.768102.55002593.93922516CS
26-10.94-78.59195402313.92162.52942294.57447431CS
52-7.74-72.201492537310.7218.71922.51861166.59444123CS
156-1513.8584-99.8035387291516.83841649.40162.51912739601.48155355CS
260-15323.1-99.980556019515326.0839916.82.523186282601.00928208CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

SONN Discussion

Ver más
tw0122 tw0122 2 semanas hace
Reverse split was September 
👍️0
Invest-in-America Invest-in-America 2 semanas hace
SONN: They announced a DUMP-to-Market routine!!! (The WORST thing any firm could do when their stock is SOARING!!!! WOW!!!!)
👍️0
Tiger Money Tiger Money 2 semanas hace
What is going on here?  Reverse?  Where is the float on this train wreck now?
👍️0
bigfart bigfart 2 semanas hace
So insiders can dump before the RS
👍️0
tw0122 tw0122 2 semanas hace
Reverse split offering and now some news $8s
👍️0
tw0122 tw0122 2 meses hace
May the reverse split gods come soon. Keep an eye!
👍️0
BooDog BooDog 2 meses hace
Another split here too.

https://www.globenewswire.com/news-release/2024/09/25/2952951/0/en/Sonnet-BioTherapeutics-Announces-1-for-8-Reverse-Stock-Split.html
👍️0
Clemdane Clemdane 3 meses hace
Big jump today!
👍️0
Awl416 Awl416 3 meses hace
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
👍️ 1
Monksdream Monksdream 3 meses hace
SONN new 52=low
👍️0
Clemdane Clemdane 3 meses hace
Big jump back up today. It's a very "risk on" stock so when the market is scared, everyone dumps it.
👍️0
Monksdream Monksdream 3 meses hace
SONN new 52 week low
👍️0
Monksdream Monksdream 3 meses hace
SONN new 52 week low
👍️0
Monksdream Monksdream 5 meses hace
SONN new 52 week low
👍️0
Monksdream Monksdream 5 meses hace
SONN new 52 week low
👍️0
BooDog BooDog 7 meses hace
I see 76 followers here. And I have a target price of around 1.50 for support.

GL.

I do own shares and am looking for this to have a good future.
👍️0
maq1214 maq1214 8 meses hace
Something must be happening behind closed doors. This stock has been ridiculously quite since the RS. Glad it’s greening again !
👍️0
81vette 81vette 8 meses hace
23,198 watchers now,word is spreading like wildfire,somebody with lots of followers must be promoting this
👍️0
81vette 81vette 8 meses hace
They are rare,not 1 in a million lotto rare but only a few per year maybe happen,the chart is great,how many bio pharma are bullish for 5 months straight (1 in a million lol) has accumulated also and that is very promising
👍️0
maq1214 maq1214 8 meses hace
Do you think we are likely to see a merger/ partnership? I;m really hoping the reverse split last year cost me a lot
👍️0
81vette 81vette 8 meses hace
$2.23 is 5 month high,next res. $5 mental,$7.57(sma200),big gaps to fill,mental 10/15/20/25 ect. lots of blue sky past 7.57,any kind of merger/buyout news could send it,thats the hype/hope/pump talk right now
👍️0
81vette 81vette 8 meses hace
254k short,could squeeze with ZERO BORROW,73% fee(no rebate),5 months of accumulation= in the know are loading
👍️0
81vette 81vette 8 meses hace
5 month uptrend(since r/s)accumulation,zero borrow,moving today on low vol(up13%),clinical trials different stages,float 2.78m,o/s 3m
👍️0
BooDog BooDog 8 meses hace
Riding free again.
👍️0
Monksdream Monksdream 9 meses hace
SONN under $2
👍️0
crowin crowin 9 meses hace
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
👍️0
maq1214 maq1214 9 meses hace
This should get exciting soon, crazy volume yesterday !
👍️0
BooDog BooDog 10 meses hace
IS it just greed or might this make good for another round trip? We'll see next week.
👍️0
BooDog BooDog 11 meses hace
Good move IMO. Surprising actually.

On December 27, 2023, the Compensation Committee (the “Committee”) of the Board of Directors of Sonnet BioTherapeutics Holdings, Inc. (the “Company”) cancelled accrued but unpaid bonuses (the “Cancelled Bonuses”) that had been awarded for fiscal years 2022 and 2023 by the Committee to certain executive officers and employees of the Company. The Cancelled Bonuses total $1,930,773.10 and include (i) $631,768.12 awarded to Pankaj Mohan, Ph.D., the Company’s President and Chief Executive Officer, (ii) $312,741.79 awarded to John Cini, Ph.D, the Company’s Chief Scientific Officer and (iii) $364,504.40 awarded to Jay Cross, the Company’s Chief Financial Officer.

https://ih.advfn.com/stock-market/NASDAQ/sonnet-biotherapeutics-SONN/stock-news/92897290/form-8-k-current-report
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
BooDog BooDog 1 año hace
Discount. Maybe I should have added "again". 1.60 offering and this is pushing towards the $. Very small float. Just playing the bounce. IF there is one lol.

https://www.accesswire.com/viewarticle.aspx?id=796208
👍️0
valleybenedetto valleybenedetto 1 año hace
Absolute piece of shit co, shit stock, dilution is endless. CEO should be fired. Sell now
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
valleybenedetto valleybenedetto 1 año hace
If they would stop shitting on shareholders, cut costs and actually get something accomplished that would be a start.
👍️0
Monksdream Monksdream 1 año hace
If the stock continues to make new lows on its way to a delisting to Cromwell Coulson’s stock market or a dissolution I will continue to record it
👍️0
valleybenedetto valleybenedetto 1 año hace
You worry about you ok?
👍️0
Monksdream Monksdream 1 año hace
You aren’t getting any money back
Time to move on
👍️0
valleybenedetto valleybenedetto 1 año hace
Not an Urban Myth ..I've already checked. They have current D and O insurance.
👍️0
Monksdream Monksdream 1 año hace
Oh goddamn tell me another urban myth
👍️0
valleybenedetto valleybenedetto 1 año hace
They have D and O insurance. That's where you collect from. That's directors and officers insurance if you didn't know
👍️0
Monksdream Monksdream 1 año hace
You wouldn’t get anything from a class action lawsuit
Anyone connected to professional asset management abandoned this company long ago
👍️0
valleybenedetto valleybenedetto 1 año hace
CEO is awful. Nothing but offerings and RS. No meaningful news in months. Class action suit might be in order here.
👍️0
Monksdream Monksdream 1 año hace
SONN new 52 week low
👍️0
Golden Cross Golden Cross 1 año hace
Might be a short play here now
👍️0
Golden Cross Golden Cross 1 año hace
Very true.....
👍️0
antman antman 1 año hace
...During his testimony, Elon Musk called short selling “a means for, in my opinion, bad people on Wall Street to steal money from small investors.”
👍️0
tw0122 tw0122 1 año hace
Biotech CEOs are mostly Wall Street whores they get compensated to short there own companies as it’s much more lucrative. They take on that toxic financing do reverse splits as part of their regular routine. Take MULN CEO for example he has no scruples or morals nor does he hide his screwing over shareholders.
As far as trading you play the post reverse splits at the right time with the low float and that is where the loot is made.
Wall Street casino.
👍️0

Su Consulta Reciente

NASDAQ
SONN
Sonnet BioTherapeutics
LSE
KLR
Keller
ASX
RHY
Rhythm Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados